Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome.

Authors:
Liping Xu Yan Zhang Na Lin Xinwei Song Qiaoding Dai

Sci Prog 2022 Apr-Jun;105(2):368504221102786

Department of Rheumatology and Immunology, 74723The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

Introduction: Eltrombopag, a kind of thrombopoietin (TPO) receptor agonist, plays the role on the megakaryocyte to activate the platelet production and rapidly increase the number of circulating platelets in patients with primary immune thrombocytopenia (ITP). Eltrombopag provides an opportunity for rapid tapering and/or cessation of corticosteroid therapy. However, it is not clear about the platelet response to Eltrombopag in ITP associated with Sjögren's Syndrome(SS).

Methods: A retrospective research was conducted on the clinical course of three patients, each with ITP secondary to SS, and initially received therapy of corticosteroids or other immunomodulatory. They took this drug for bleeding diseases. Referring to the description, Eltrombopag was prescribed and adjusted with an initial dose of 25 mg daily, then weekly, then monthly according to the monitoring of platelet counts.

Results: All patients maintained a satisfactory level of platelet counts (>100,000/mm for >2 years) following corticosteroid withdrawal. Meanwhile, Eltrombopag was well-tolerated, and there were no adverse effects, such as thrombotic events.

Conclusions: Eltrombopag is effective and safe for patients with ITP associated with SS during corticosteroid withdrawal. Thus it may be a crucial therapeutic strategy for reducing corticosteroid-related side effects in SS patients with ITP.

Download full-text PDF

 Source
http://dx.doi.org/10.1177/00368504221102786DOI Listing
May 2022

Publication Analysis

Top Keywords

patients itp
12
itp associated
8
corticosteroid withdrawal
8
eltrombopag
7
patients
6
itp
5
effects patients
4
received therapy
4
initial dose
4
adjusted initial
4
prescribed adjusted
4
eltrombopag prescribed
4
description eltrombopag
4
referring description
4
diseases referring
4
bleeding diseases
4
drug bleeding
4
immunomodulatory drug
4
corticosteroids immunomodulatory
4
therapy corticosteroids
4

Keyword Occurance

Similar Publications

Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia.

Authors:
Roszymah Hamzah Nurasyikin Yusof Nor Rafeah Tumian Suria Abdul Aziz Nur Syahida Mohammad Basri Tze Shin Leong Kim Wah Ho Veena Selvaratnam Sen Mui Tan Siti Afiqah Muhamad Jamil

J Blood Med 2022 21;13:337-349. Epub 2022 Jun 21.

Faculty of Computer and Mathematical Sciences, Universiti Teknologi Mara, Shah Alam, Selangor, Malaysia.

Background: Immune thrombocytopenia (ITP) is well characterized in Western, European and other Asia-Pacific countries. Nevertheless, the clinical epidemiology, treatment pattern and disease outcome of ITP in Malaysia are still limited and not well known.

Objective: This study aimed to describe the clinical epidemiology, treatment outcome and mortality of ITP patients in haematology tertiary multicentre in Malaysia. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Contribution of interleukin 27 serum level to pathogenesis and prognosis in children with immune thrombocytopenia.

Authors:
Tamer Hassan Doaa Abdel Rahman Nermin Raafat Manar Fathy Mohamed Shehab Ahmed Hosny Reham Fawzy Marwa Zakaria

Medicine (Baltimore) 2022 Jun 24;101(25):e29504. Epub 2022 Jun 24.

Pediatrics & Biochemistry Department, Zagazig University, Zagazig University Street 1, Zagazig, 44519, Egypt.

Abstract: Concepts surrounding the mechanisms of thrombocytopenia in ITP have shifted from the traditional view of autoantibody mediated platelet destruction to more complex mechanisms in which impaired platelet production, T-cell-mediated effects, and disturbed cytokine profiles play a role. Interleukin 27 (IL-27) plays pleiotropic roles in immunomodulation and autoimmune diseases.We aimed to determine the level of IL-27 in patients with ITP and its relationship to patient and disease characteristics as well as disease chronicity and response to treatment. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Frequency and utility of bone marrow examination in relapsed/ refractory immune thrombocytopenia.

Authors:
Kritika Taparia Erika Wall Donald M Arnold Haowei Linda Sun

J Thromb Haemost 2022 Jun 25. Epub 2022 Jun 25.

Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Background: The diagnosis of immune thrombocytopenia (ITP) is one of exclusion. While guidelines recommend against routine bone marrow examination (BME) at time of ITP diagnosis, the role of BME in relapsed/refractory ITP is unclear.

Objectives: To examine the frequency and predictors of BME in relapsed/refractory ITP. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Regulatory T cells are replenished in the splenic microenvironment of patients with immune thrombocytopenia by treatment with thrombopoietin receptor agonists.

Authors:
Rick Kapur

Br J Haematol 2022 Jun 24. Epub 2022 Jun 24.

Sanquin Research, Department of Experimental Immunohematology, Amsterdam and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Therapeutic management of patients with immune thrombocytopenia (ITP) remains challenging; however, thrombopoietin receptor agonists (TPO-RAs) have revolutionised the treatment landscape of ITP. It is increasingly hypothesised that TPO-RAs may have an immune modulatory role and Pizzi and colleagues provide evidence in support of this by demonstrating that TPO-RA treatment restores the decreased regulatory T cell (Treg) numbers in the splenic microenvironment of patients with ITP. Commentary on: Pizzi M, Vianello F, Binotto G, Vianelli N, Carli G, Auteri G, et al. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Splenectomy in İmmune Thrombocytopenia: A Retrospective Analysis of 25-Year Follow-up Data from a Tertiary Health Clinic.

Authors:
Serdar Ozkok Isik Kaygusuz Atagunduz Osman Kara Aslihan Sezgin Toluy Ozgumus Fatma Gecgel Tulin Firatli Tuglular Tayfur Toptas

Indian J Hematol Blood Transfus 2022 Jul 15;38(3):516-521. Epub 2021 Jul 15.

Department of Hematology, Faculty of Medicine, Marmara University, İstanbul, Turkey.

Immune thrombocytopenia (ITP) is a rare autoimmune disorder presenting with isolated thrombocytopenia. Splenectomy is still one of the treatment alternatives for these patients. Here we aim to analyze long term follow-up data of splenectomy in immune thrombocytopenia. Read More

View Article and Full-Text PDF
July 2022
Similar Publications
}